Results 51 to 60 of about 31,226 (229)

Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration [PDF]

, 2016
Purpose To define a minimum set of outcome measures for tracking, comparing, and improving macular degeneration care. Design Recommendations from a working group of international experts in macular degeneration outcomes registry development and patient ...
Barthelmes, D. (Daniel), Blumenkranz, M. (Mark), Cheung, G. (Gemmy), Gillies, M.C. (Mark), Haller, J. (Julia), Johnston, R. (Robert), Kim, R. (Ramasamy), Klaver, C.C.W. (Caroline), McKibbin, M. (Martin), Ngah, N.F. (Nor Fariza), Pershing, S. (Suzann), Rodrigues, I.A. (Ian A.), Shankar, D. (Dato), Sprinkhuizen, S.M. (Sara M.), Tamura, H. (Hiroshi), Tufail, A. (Adnan), Weng, C.Y. (Christina Y.), Westborg, I. (Inger), Yelf, C. (Catherine), Yoshimura, N.   +19 more
core   +2 more sources

Non‐physician delivered intravitreal injection service: A systematic review of safety, implementation, training and patient experience

Acta Ophthalmologica, EarlyView.
Abstract The global demand for intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy continues to rise, straining ophthalmic capacity worldwide. Task shifting from physicians to trained non‐physician healthcare professionals has emerged as a potential strategy to expand service delivery.
Trang Truong Laursen, Haris Bralic, Jakob Grauslund, Yousif Subhi, Lonny Stokholm   +4 more
wiley   +1 more source

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice [PDF]

, 2016
Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility ...
Butt, T, Rubin, G, Tufail, A
core   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment : evidence from the RESTORE trial [PDF]

, 2012
Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare ...
Mitchell, Paul, Annemans, Lieven, Gallagher, Meghan, Hasan, Rafiq, Thomas, Simu, Gairy, Kerry, Knudsen, Martin, Onwordi, Henrietta   +7 more
core   +2 more sources

Aflibercept for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews, 2016
Central vision loss caused by age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called ...
Salman, Sarwar, Elizabeth, Clearfield, Mohamed Kamel, Soliman, Mohammad Ali, Sadiq, Andrew J, Baldwin, Mostafa, Hanout, Aniruddha, Agarwal, Yasir J, Sepah, Diana V, Do, Quan Dong, Nguyen   +9 more
openaire   +3 more sources

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Management of neovascular age-related macular degeneration: Taiwan expert consensus

Journal of the Formosan Medical Association, 2021
Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ...
Ling Yeung, Yi-Ting Hsieh, Chang-Hao Yang, Lee-Jen Chen, Shih-Jen Chen, Cheng-Kuo Cheng, Shwu-Jiuan Sheu, Ching-Yao Tsai, Tsung-Tien Wu, Wei-Chi Wu, San-Ni Chen   +10 more
doaj   +1 more source

The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy (OMEGA) study: Geographic atrophy progression in fundus autofluorescence ‐ OMEGA report 3

Acta Ophthalmologica, EarlyView.
Abstract Purpose To measure the progression of geographic atrophy (GA) in subjects with age‐related macular degeneration (AMD) in a natural history study. Methods We analysed fundus autofluorescence (FAF) images using a semiautomatic method (RegionFinder) to quantify the GA area in a monocentric study.
Philippe Valmaggia, Georg Ansari, Nadja Inglin, Nils Schärer, Hanna Zuche, Chrysoula Gabrani, Faady Yahya, Marco Cattaneo, Kristina Pfau, Andrea Giani, Marieh Esmaeelpour, Taffeta Chingning Yamaguchi, Christian Prünte, Hendrik P. N. Scholl, Nicolas Feltgen, Leopold Schmetterer, Maximilian Pfau, Peter M. Maloca   +17 more
wiley   +1 more source

Photo-damage, photo-protection and age-related macular degeneration [PDF]

, 2015
Age-related macular degeneration (AMD) is a degenerative retinal disease that causes blindness in people 60-65 years and older, with the highest prevalence appearing in people 90 years-old or more.
Marquioni Ramella, Melisa Daniela, Suburo, Angela Maria   +1 more
core   +1 more source